{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:54:09Z","timestamp":1793681649897,"version":"4.5.1"},"reference-count":46,"publisher":"Consortium of Multiple Sclerosis Centers","issue":"Theme","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Latin America (LATAM) is a diverse region with more than 30 countries, each varying in cultural, economic, and social aspects. While multiple sclerosis (MS) care in LATAM has improved, there are still challenges to address. Epidemiologic studies have shown varying incidence rates of MS in the region, influenced by factors such as genetics, environmental conditions, and regional diversity. Scientific research on MS in LATAM has increased, with publications and consensus guidelines emerging. However, access to disease-modifying treatments remains a significant challenge in many countries due to affordability issues and limited availability of certain therapies. The region also faces obstacles in providing comprehensive MS care, including rehabilitation programs and diagnosis tools. There are collaborative efforts and initiatives in LATAM that are working toward overcoming these challenges and improving the overall quality of care for people with MS in the region.<\/jats:p>","DOI":"10.7224\/1537-2073.2024-085","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T02:17:47Z","timestamp":1741745867000},"page":"T7-T12","source":"Crossref","is-referenced-by-count":7,"title":["Multiple Sclerosis Care in Latin America"],"prefix":"10.7224","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8380-938X","authenticated-orcid":false,"given":"Valeria","family":"Rocha","sequence":"first","affiliation":[{"name":"From Direccion Nacional de Sanidad Policial, CASMU IAMPP, Hospital Brit\u00e1nico, Montevideo, Uruguay"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Navas","sequence":"additional","affiliation":[{"name":"Clinica Colombia, Hospital San Jose, Bogot\u00e1, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4242","published-online":{"date-parts":[[2024,12,1]]},"reference":[{"key":"2025031206173950000_b1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.msard.2018.03.014","article-title":"Evolution of multiple sclerosis prevalence and phenotype in Latin America","volume":"22","author":"Negrotto","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"2025031206173950000_b2","doi-asserted-by":"crossref","first-page":"1368675","DOI":"10.3389\/fepid.2024.1368675","article-title":"Multiple sclerosis in Central America and Caribbean countries: frequency and clinical characterization of an emergent disease","volume":"4","author":"Gracia","year":"2024","journal-title":"Front Epidemiol"},{"issue":"5","key":"2025031206173950000_b3","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1159\/000538221","article-title":"Incidence of multiple sclerosis in Uruguay: a prospective population-based study","volume":"58","author":"Rocha","year":"2024","journal-title":"Neuroepidemiology"},{"issue":"2","key":"2025031206173950000_b4","first-page":"2055217317715050","article-title":"Multiple sclerosis epidemiology in Latin America: an updated survey","volume":"3","author":"Cristiano","year":"2017","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"6","key":"2025031206173950000_b5","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.autrev.2009.11.001","article-title":"HLA class II polymorphism in Latin American patients with multiple sclerosis","volume":"9","author":"Rojas","year":"2010","journal-title":"Autoimmun Rev."},{"key":"2025031206173950000_b6","first-page":"2055217315600193","article-title":"Multiple sclerosis in Latin America: a different disease course severity? A collaborative study from the MSBase Registry","volume":"1","author":"Rojas","year":"2015","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"8","key":"2025031206173950000_b7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11910-017-0768-4","article-title":"Multiple sclerosis in Latin Americans: genetic aspects","volume":"17","author":"Rivera","year":"2017","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"1","key":"2025031206173950000_b8","first-page":"131","article-title":"Serum vitamin D concentration and its relationship with the severity and behavior of the disease in a group of patients with multiple sclerosis treated in the Pichincha region of Ecuador. E-poster LACTRIMS 2016","volume":"23","author":"Zambrano","year":"2017","journal-title":"Mult Scler"},{"issue":"1","key":"2025031206173950000_b9","first-page":"2055217317700668","article-title":"Access and barriers to MS care in Latin America","volume":"3","author":"Rivera","year":"2017","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"2025031206173950000_b10","first-page":"2055217316666407","article-title":"Prevalence of multiple sclerosis in Latin America and its relationship with European migration","volume":"2","author":"Correa","year":"2016","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"7","key":"2025031206173950000_b11","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3109\/08916934.2011.592887","article-title":"Multiple sclerosis in Caucasians and Latino Americans","volume":"44","author":"Aguirre-Cruz","year":"2011","journal-title":"Autoimmunity"},{"issue":"11","key":"2025031206173950000_b12","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1007\/s10072-020-04680-3","article-title":"Clinical and demographic characteristics of primary progressive multiple sclerosis in Argentina: Argentinean registry cohort study (RelevarEM)","volume":"41","author":"Alonso","year":"2020","journal-title":"Neurol Sci"},{"issue":"2","key":"2025031206173950000_b13","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.msard.2012.09.001","article-title":"Multiple sclerosis in Colombia and other Latin American countries","volume":"2","author":"Toro","year":"2013","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"2025031206173950000_b14","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000337162","article-title":"Therapeutic armamentarium and health system coverage of multiple sclerosis in Latin America","volume":"38","author":"Gracia","year":"2012","journal-title":"Neuroepidemiology"},{"key":"2025031206173950000_b15","author":"Multiple sclerosis Latin America","journal-title":"Search Results - PubMed"},{"key":"2025031206173950000_b16","doi-asserted-by":"crossref","first-page":"116609","DOI":"10.1016\/j.jns.2019.116609","article-title":"Consensus recommendations on the management of multiple sclerosis patients in Argentina","volume":"409","author":"Cristiano","year":"2020","journal-title":"J Neurol Sci"},{"issue":"8","key":"2025031206173950000_b17","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1590\/0004-282x20180078","article-title":"Brazilian consensus for the treatment of multiple sclerosis: Brazilian Academy of Neurology and Brazilian Committee on Treatment and Research in Multiple Sclerosis","volume":"76","author":"Marques","year":"2018","journal-title":"Arq Neuropsiquiatr"},{"key":"2025031206173950000_b18","doi-asserted-by":"crossref","first-page":"103053","DOI":"10.1016\/j.msard.2021.103053","article-title":"Clinical practice patterns in multiple sclerosis management: Mexican consensus recommendations","volume":"53","author":"Skromne-Eisenberg","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"2025031206173950000_b19","doi-asserted-by":"crossref","first-page":"667398","DOI":"10.3389\/fneur.2021.667398","article-title":"Clinical pathway for the diagnosis and management of patients with relapsing-remitting multiple sclerosis: a first proposal for the Peruvian population","volume":"12","author":"Capar\u00f3-Zamalloa","year":"2021","journal-title":"Front Neurol"},{"key":"2025031206173950000_b20","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jns.2018.07.024","article-title":"Consensus recommendations for the diagnosis and treatment of primary progressive multiple sclerosis in Latin America","volume":"393","author":"Cristiano","year":"2018","journal-title":"J Neurol Sci"},{"key":"2025031206173950000_b21","first-page":"10","article-title":"The evolution of knowledge on multiple sclerosis. Reflection in Latin America: the past decades, the present and future challenges","volume":"2","author":"Rivera","year":"2013","journal-title":"Lat Am Mult Scler J."},{"issue":"2","key":"2025031206173950000_b22","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"key":"2025031206173950000_b23","doi-asserted-by":"crossref","first-page":"102043","DOI":"10.1016\/j.msard.2020.102043","article-title":"Application of the 2017 McDonald criteria for the diagnosis of multiple sclerosis after a first demyelinating event in patients from Argentina","volume":"41","author":"Pagani Cassar\u00e1","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"2025031206173950000_b24","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/1352458519898590","article-title":"Barriers to access and utilization of multiple sclerosis care services in a large cohort of Latin American patients","volume":"27","author":"Carnero Contentti","year":"2021","journal-title":"Mult Scler"},{"issue":"18","key":"2025031206173950000_b25","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1212\/WNL.0000000000000376","article-title":"Multiple sclerosis care in Latin America","volume":"82","author":"Rivera","year":"2014","journal-title":"Neurology"},{"key":"2025031206173950000_b26","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jns.2017.08.3242","article-title":"Follow-on products for treatment of multiple sclerosis in Latin America: an update","volume":"381","author":"Correale","year":"2017","journal-title":"J Neurol Sci"},{"issue":"5","key":"2025031206173950000_b27","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1177\/1352458518807082","article-title":"The Multiple Sclerosis Care Unit","volume":"25","author":"Soelberg Sorensen","year":"2019","journal-title":"Mult Scler"},{"key":"2025031206173950000_b28","doi-asserted-by":"crossref","first-page":"118072","DOI":"10.1016\/j.jns.2021.118072","article-title":"Multiple sclerosis care units in Latin America: consensus recommendations about its objectives and functioning implementation","volume":"429","author":"Cristiano","year":"2021","journal-title":"J Neurol Sci"},{"issue":"7","key":"2025031206173950000_b29","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1177\/1352458516636474","article-title":"All relapsing multiple sclerosis patients should be managed at a specialist clinic - YES","volume":"22","author":"Brownlee","year":"2016","journal-title":"Mult Scler"},{"issue":"3","key":"2025031206173950000_b30","first-page":"2055217317723369","article-title":"Disease-modifying therapies in multiple sclerosis in Latin America","volume":"3","author":"Skromne-Eisenberg","year":"2017","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"3","key":"2025031206173950000_b31","first-page":"2055217317727295","article-title":"The genetics of multiple sclerosis in Latin America","volume":"3","author":"Rivas Alonso","year":"2017","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"2025031206173950000_b32","author":"Multiple Sclerosis International Federation","journal-title":"Atlas of MS"},{"issue":"2","key":"2025031206173950000_b33","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.vhri.2012.09.015","article-title":"Potential regulatory and commercial environment for biosimilars in Latin America","volume":"1","author":"Azevedo","year":"2012","journal-title":"Value Health Reg Issues"},{"issue":"2","key":"2025031206173950000_b34","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40120-019-0139-y","article-title":"Practical issues concerning the approval and use of biosimilar drugs for the treatment of multiple sclerosis in Latin America","volume":"8","author":"Steinberg","year":"2019","journal-title":"Neurol Ther"},{"issue":"2","key":"2025031206173950000_b35","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s40120-019-0145-0","article-title":"Biosimilar drugs for multiple sclerosis: an unmet international need or a regulatory risk?","volume":"8","author":"Rivera","year":"2019","journal-title":"Neurol Ther"},{"issue":"7","key":"2025031206173950000_b36","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrneurol.2017.81","article-title":"Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis","volume":"13","author":"Muraro","year":"2017","journal-title":"Nat Rev Neurol"},{"key":"2025031206173950000_b37","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/B978-0-323-90242-7.00019-5","article-title":"Ongoing randomized clinical trials on HSCT in multiple sclerosis","volume":"202","author":"Inglese","year":"2024","journal-title":"Handb Clin Neurol"},{"issue":"4","key":"2025031206173950000_b38","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1159\/000469655","article-title":"A feasibility study of the full outpatient conduction of hematopoietic transplants in persons with multiple sclerosis employing autologous non-cryopreserved peripheral blood stem cells","volume":"137","author":"Ruiz-Arg\u00fcelles","year":"2017","journal-title":"Acta Haematol"},{"key":"2025031206173950000_b39","doi-asserted-by":"crossref","first-page":"647425","DOI":"10.3389\/fneur.2021.647425","article-title":"The 1,000th transplant for multiple sclerosis and other autoimmune disorders at the HSCT-M\u00e9xico Program: a myriad of experiences and knowledge","volume":"12","author":"Murrieta-\u00c1lvarez","year":"2021","journal-title":"Front Neurol"},{"issue":"1","key":"2025031206173950000_b40","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.transproceed.2023.12.004","article-title":"Second autologous hematopoietic stem cell transplantation in multiple sclerosis: a single-center prospective experience","volume":"56","author":"Hern\u00e1ndez-Flores","year":"2024","journal-title":"Transplant Proc"},{"issue":"5","key":"2025031206173950000_b41","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1001\/jamaneurol.2018.4905","article-title":"Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis","volume":"76","author":"Harding","year":"2019","journal-title":"JAMA Neurol"},{"issue":"4","key":"2025031206173950000_b42","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","article-title":"Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study","volume":"19","author":"He","year":"2020","journal-title":"Lancet Neurol"},{"issue":"8","key":"2025031206173950000_b43","doi-asserted-by":"crossref","first-page":"e1041","DOI":"10.1212\/WNL.0000000000010135","article-title":"Initial high-efficacy disease-modifying therapy in multiple sclerosis: a nationwide cohort study","volume":"95","author":"Buron","year":"2020","journal-title":"Neurology"},{"issue":"10","key":"2025031206173950000_b44","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamaneurol.2021.2738","article-title":"Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis: data from 2 different national strategies","volume":"78","author":"Spelman","year":"2021","journal-title":"JAMA Neurol"},{"key":"2025031206173950000_b45","doi-asserted-by":"crossref","first-page":"104935","DOI":"10.1016\/j.msard.2023.104935","article-title":"Evaluation of the use of high-efficacy treatments (HETs) in patients with relapsing-remitting multiple sclerosis in Argentina","volume":"79","author":"Alonso","year":"2023","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"2025031206173950000_b46","first-page":"2055217317720845","article-title":"The challenges and opportunities of multiple sclerosis care in Latin America","volume":"3","author":"Ontaneda","year":"2017","journal-title":"Mult Scler J Exp Transl Clin"}],"container-title":["International Journal of MS Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/ijmsc\/article-pdf\/27\/Theme\/T7\/3499079\/i1537-2073-27-t7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/ijmsc\/article-pdf\/27\/Theme\/T7\/3499079\/i1537-2073-27-t7.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T21:13:24Z","timestamp":1752786804000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijmsc.org\/view\/multiple-sclerosis-care-in-latin-america"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,1]]},"references-count":46,"journal-issue":{"issue":"Theme","published-online":{"date-parts":[[2024,12,1]]},"published-print":{"date-parts":[[2024,12,1]]}},"URL":"https:\/\/doi.org\/10.7224\/1537-2073.2024-085","relation":{},"ISSN":["1537-2073"],"issn-type":[{"value":"1537-2073","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,1]]}}}